This is a working overview of Peptide mapping, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-19. Anything still debated is marked as such rather than presented as settled.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Seven residues; tuftsin plus a Pro-Gly-Pro tail |
| Molecular formula | C33H57N11O9 | Commonly reported value for the free peptide |
| Monoisotopic mass | Roughly 751.4 Da | Average molecular mass near 751.9 Da |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Freely soluble in water | Also dissolves in saline and other polar solvents |
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
=== EC 1.11.2 Peroxygenase === EC 1.11.2.1: unspecific peroxygenase EC 1.11.2.2: myeloperoxidase EC 1.11.2.3: plant seed peroxygenase EC 1.11.2.4: fatty-acid peroxygenase EC 1.11.2.5: 3-methyl-L-tyrosine peroxygenase EC 1.11.2.6: L-tyrosine peroxygenase
In Mexico, Applied Biosystems collaborated with the National Institute of Genomic Medicine of Mexico (Instituto Nacional de Medicina Genomica or INMEGEN), and established an Applied Biosystems Sequencing and Genotyping Unit at INMEGEN. In 2006, Applied Biosystems acquired the Research Products Division of Ambion, a supplier of RNA-based reagents and products. That year, with the Influenza A Subtype H5N1 "avian flu" strain scare, the company launched a global initiative to identify and track such infectious diseases. In 2006, Applied Biosystems also acquired Agencourt Personal Genomics, located in Beverly, MA, to commercialize Agencourt's SOLiD sequencing system. In 2007, ABI Solid Sequencing, a next-gen DNA sequencing platform, was announced. Mark Stevenson was appointed president and chief operating officer of Applied Biosystems. In November 2008, Applied Biosystems merged with Invitrogen, forming Life Technologies, which was acquired by Thermo Fisher Scientific in 2014.
== Mechanism of action == The mechanism of action is not fully understood, but nitrofurazone's antimicrobial properties are suspected to be due to the interference of DNA synthesis in the microorganism by inhibiting certain enzymes that are involved with glycolysis. Other enzymes this may affect include, pyruvate dehydrogenase, citrate synthetase, malate dehydrogenase, glutathione reductase, and pyruvate decarboxylase.
Sources: en.wikipedia.org
Another submarine, USS Cavalla, was able to maneuver to an attack position on the 25,675-ton carrier Shōkaku by about noon. The submarine fired a spread of six torpedoes, three of which struck Shōkaku on her starboard side. Badly damaged, the carrier came to a halt. One torpedo had hit the forward aviation fuel tanks near the main hangar, and aircraft that had just landed and were being refueled exploded into flames. Ammunition and exploding bombs added to the conflagration, as did burning fuel spewing from shattered fuel pipes. With her bows subsiding into the sea and fires out of control, the captain gave orders to abandon ship. Within minutes, there was a catastrophic explosion of aviation fuel vapor which had built up between decks, which blew the ship apart. The carrier rolled over and sank about 140 miles (230 km) north of the island of Yap. 887 crew and 376 men of the 601st Naval Air Group, 1,263 men in all, were killed. There were 570 survivors, including the carrier's commanding officer, Captain Hiroshi Matsubara. Destroyer Urakaze attacked the submarine, but Cavalla escaped with relatively minor damage despite near misses from depth charges. Meanwhile, Taihō was falling victim to poor damage control. Hoping to clear the explosive fumes, an inexperienced damage-control officer ordered her ventilation system to operate at full blast. This action instead spread the vapors throughout Taihō, putting the entire vessel at risk.
Rudolph Emile 'Rudy' Tanzi is the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University, and director of the Genetics and Aging Research Unit and director of the Henry and Allison McCance Center for Brain Health at Massachusetts General Hospital (MGH). Dr. Rudy Tanzi has been investigating the genetics of neurological disease since the 1980s. He co-discovered all three familial early-onset Alzheimer's disease (FAD) genes and several other neurological disease genes including that responsible for Wilson’s disease. His team was the first to use human stem cells to create three-dimensional cell culture organoids of AD, dubbed “Alzheimer's-in-a-Dish”. The 3-D model made drug screening for AD faster and more cost-effective. He has published over 800 research papers and has received the Metropolitan Life Award and Potamkin Prize, the two highest awards for Alzheimer’s research. He is also a member of the National Academy of Medicine and was on the TIME100 Most Influential People in the World list in 2015.
Journal of Military History. 65 (3): 617–640. doi:10.2307/2677528. JSTOR 2677528. S2CID 159945703. McEvedy, Colin; Jones, Richard (1978). Atlas of World Population History. Facts on File. ISBN 978-0-87196-402-1. McLynn, Frank (1998). Napoleon: A Biography. Pimlico. ISBN 978-0-7126-6247-5. Munch-Petersen, Thomas (2007). Defying Napoleon: How Britain Bombarded Copenhagen and Seized the Danish Fleet in 1807. Sutton. ISBN 978-0-7509-4280-5. Palmer, Robert Roswell (1941). Twelve who Ruled: The Committee of Public Safety, During the Terror. Princeton University Press. Palmer, Alan (1974). Alexander I: Tsar of War and Peace. Weidenfeld & Nicolson. ISBN 978-0-297-76700-8. Palmer, R. R.; Colton, Joel; Kramer, Lloyd (2013). A History of the Modern World: 11th Edition. McGraw-Hill Higher Education. ISBN 978-0-07-759962-1. Payne, Stanley G. (1973). A History of Spain and Portugal: Eighteenth Century to Franco. Vol. 2. Madison: University of Wisconsin Press. ISBN 978-0299062705. Retrieved 2 May 2021. Philo, Tom (2010), Military and Civilian War Related Deaths Through the Ages, archived from the original on 20 April 2010 Rapport, Mike (2013). The Napoleonic Wars: A Very Short Introduction. OUP Oxford. ISBN 978-0-19-164251-7. Riehn, Richard K. (1990). 1812: Napoleon's Russian Campaign. McGraw-Hill. ISBN 978-0-07-052731-7. Riehn, Richard K. (1991), 1812: Napoleon's Russian Campaign (Paperback ed.), New York: Wiley, ISBN 978-0-471-54302-2 Riley, J. P. (2013). Napoleon and the World War of 1813: Lessons in Coalition Warfighting. Routledge. ISBN 978-1-136-32135-1. Roberts, Andrew (2014).
Sources: en.wikipedia.org
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.
No peptide with this exact sequence has been identified as an endogenous substance. It is a laboratory-designed analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The Pro-Gly-Pro extension has no known natural source.
Proline introduces conformational constraints that make a peptide less accessible to common peptidases. This is a standard stabilization strategy in peptide design. The added residues also increase the distance between the active tuftsin portion and typical cleavage sites.
Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.